Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located
in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adult with head and neck cancer. The study assessed the safety,
and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy
in patients with advanced non-small cell lung cancer (NSCLC).